TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.

Trial Details

NCT ID
NCT05948813
Phase
PHASE2
Sponsor
TYK Medicines, Inc
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TY-9591
  • Osimertinib
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Male or female aged ≥18 years and \<80 years.
  • Patients diagnosed with NSCLC by histology or cytology, with brain metastases.
  • Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with othe…
  • No prior systemic antitumor therapy for locally advanced or metastatic NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →